Acute Ischemic Stroke Therapeutics Market Report 2024

This Acute Ischemic Stroke Therapeutics market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The acute ischemic stroke therapeutics market size has grown strongly in recent years. It will grow from $8.47 billion in 2023 to $9.24 billion in 2024 at a compound annual growth rate (CAGR) of 9%. The growth observed during the historic period can be attributed to several factors, including an increase in the number of patients, a rise in the geriatric population, a growing prevalence of obesity, a higher incidence of ischemic stroke, and an increase in hypertension.

The acute ischemic stroke therapeutics market size is expected to see strong growth in the next few years. It will grow to $13.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth during the forecast period can be attributed to several factors, including a growing preference for online pharmacies, an increase in cardiovascular diseases, rising cholesterol levels, a higher prevalence of diseases, and a greater incidence of ischemic stroke. Key trends expected during this period include advancements in medical technology, the integration of artificial intelligence, the adoption of machine learning, progress in neurology, and the use of advanced diagnostic technologies.

The increasing prevalence of hypertension is expected to drive the growth of the acute ischemic stroke therapeutics market in the coming years. Hypertension, or high blood pressure, is a condition where the force of blood against the artery walls remains consistently high, raising the risk of heart disease, stroke, and other health issues. This rise in hypertension is largely attributed to an aging population and higher obesity rates. Acute ischemic stroke therapies help manage hypertension by treating stroke-related complications and preventing further cerebrovascular damage, which is often linked to elevated blood pressure. For example, in May 2023, the UK’s National Health Service England reported that about 30% of adults in the US had hypertension, with 15% having untreated cases. The prevalence of hypertension also increases with age, ranging from 9% in adults aged 16-44 to 60% in those aged 65 and older. Thus, the growing incidence of hypertension is fueling the expansion of the acute ischemic stroke therapeutics market.

Leading companies in the acute ischemic stroke therapeutics market are advancing medical technologies through innovative solutions such as exosome-based therapy to enhance treatment efficacy and patient outcomes. Exosome-based therapy is a novel approach focusing on using exosomes, small extracellular vesicles (30-150 nm in diameter) released by cells, which play a role in cell-to-cell communication. For instance, in January 2024, Aruna Bio, a US-based developer of neural exosome platforms, received FDA clearance for its investigational new drug application for AB126. This marks the first exosome-based therapy to enter human clinical trials targeting acute ischemic stroke. A Phase 1b/2a clinical trial is scheduled to begin in early 2024 to evaluate the safety, tolerability, and preliminary efficacy of AB126 in patients with poor prognosis following thrombectomy. Derived from proprietary neural stem cells, AB126 has demonstrated anti-inflammatory and neuroprotective effects in preclinical studies and is capable of crossing the blood-brain barrier.

In June 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for an undisclosed amount. This acquisition aims to enhance Johnson & Johnson’s immunology portfolio by integrating innovative bispecific antibodies to address unmet needs in atopic dermatitis and asthma. It also seeks to develop advanced therapeutics through dual targeting of disease pathways. Proteologix Inc., a US-based provider of drug discovery and development solutions, specializes in targeted protein degradation.

Major companies operating in the acute ischemic stroke therapeutics market are Johnson & Johnson, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Medtronic plc, Eli Lilly and Company, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Genentech Inc., NoNO Inc., Athersys Inc., XBiotech Inc., ZZ Biotech LLC.

North America was the largest region in the acute ischemic stroke therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute ischemic stroke therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute ischemic stroke therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute ischemic stroke therapeutics refer to the medical treatments and interventions used to manage and treat ischemic stroke, which occurs when a blood clot obstructs or narrows an artery leading to the brain, resulting in a sudden reduction of blood flow and oxygen to brain tissue. The primary objective of these therapeutics is to restore blood flow to the affected brain area as quickly as possible to reduce brain damage and enhance outcomes.

The main types of acute ischemic stroke therapeutics include thrombolytic therapeutics, antihypertensive therapeutics, antiplatelet therapeutics, and anticoagulants. Thrombolytic therapeutics are medications aimed at dissolving blood clots and reestablishing normal blood flow in conditions such as heart attacks, strokes, and pulmonary embolisms. These medications can be administered orally or parenterally and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in settings such as hospitals, ambulatory surgical centers, and diagnostic centers.

The acute ischemic stroke therapeutics market research report is one of a series of new reports that provides acute ischemic stroke therapeutics market statistics, including acute ischemic stroke therapeutics industry global market size, regional shares, competitors with acute ischemic stroke therapeutics market share, detailed acute ischemic stroke therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the acute ischemic stroke therapeutics industry. This acute ischemic stroke therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute ischemic stroke therapeutics market consists of revenues earned by entities by providing services such as mechanical thrombectomy, antiplatelet therapy, rehabilitation services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute ischemic stroke therapeutics market also includes sales of antiplatelet agents, mechanical thrombectomy devices, neuroprotective agents, and anticoagulants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.